Vivek Subbiah shared a post on LinkedIn:

“Just landed in Paris! Looking forward to delivering the keynote at the esteemed PRISM center in Paris, France.

If you are here in Paris, it’s free to attend – registration info below.

Huge thanks to the incredible Dr. Fabrice André for the invitation, PRISM center – National Precision Oncology Center – A unique partnership between Gustave Roussy, Centrale Supélec, Université Paris-Saclay, Groupe Unicancer, and Inserm.

Paris Precision Oncology = Perfect synergy of place, people, and purpose.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.
OncoDaily